Compare DexCom, Inc. (DXCM) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.44 (market cap $39.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| DXCM | TTWO | |
|---|---|---|
Market Cap | $31.86B | $39.15B |
Volume | 3,607,070 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $92.34 | $262.29 |
52-Week Low | $54.84 | $189.69 |
Typical Hold Time | 62 Days | 111 Days |
Enterprise Value | $31.32B | $40.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Take-Two Interactive (TTWO) trades at $209.37, up 2.63% on the day, with a bullish technical signal and strong analyst support. The stock is supported by anticipation for Grand Theft Auto VI's November 2026 launch, though recent earnings have been mixed with a Q2 2026 miss. Fundamentals show significant revenue growth to $5.63 billion in 2025 but deep net losses, with a negative net income margin of -79.51%. Cash flow improved in 2025 due to financing activities, but operating cash flow remains negative.
The outlook is optimistic due to GTA VI's potential, with a consensus price target of $292.30 implying 40% upside. However, risks include persistent profitability challenges, high debt levels, and execution risks around the key title launch. Investor sentiment is buoyant, but the stock's valuation relies heavily on future game performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
